# BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE

> **NCT06538077** · PHASE4 · RECRUITING · sponsor: **Post Graduate Institute of Medical Education and Research, Chandigarh** · enrollment: 336 (estimated)

## Conditions studied

- Hepatic Encephalopathy
- Decompensated Cirrhosis
- Minimal Hepatic Encephalopathy

## Interventions

- **DRUG:** Oral Branched chain Amino acid
- **DRUG:** Rifaximin 550 MG
- **DRUG:** Lactulose
- **DRUG:** Placebo for BCAA
- **DRUG:** Placebo for Rifaximin 550mg

## Key facts

- **NCT ID:** NCT06538077
- **Lead sponsor:** Post Graduate Institute of Medical Education and Research, Chandigarh
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-01
- **Primary completion:** 2026-08
- **Final completion:** 2027-08
- **Target enrollment:** 336 (ESTIMATED)
- **Last updated:** 2025-06-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06538077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06538077, "BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06538077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*